Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 117

1.

Expression of Serpin Peptidase Inhibitor B2 (SERPINB2) is regulated by Aryl hydrocarbon receptor (AhR).

Brauze D, Kiwerska K, Bednarek K, Grenman R, Janiszewska J, Giefing M, Jarmuz-Szymczak M.

Chem Biol Interact. 2019 Aug 25;309:108700. doi: 10.1016/j.cbi.2019.06.013. Epub 2019 Jun 7.

PMID:
31176714
2.

Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.

Jin Y, Liang ZY, Zhou WX, Zhou L.

Hepatol Int. 2019 Mar;13(2):180-189. doi: 10.1007/s12072-018-9920-8. Epub 2019 Jan 1.

PMID:
30600477
3.
4.

SERPINB2 is a novel TGFβ-responsive lineage fate determinant of human bone marrow stromal cells.

Elsafadi M, Manikandan M, Atteya M, Abu Dawud R, Almalki S, Ali Kaimkhani Z, Aldahmash A, Alajez NM, Alfayez M, Kassem M, Mahmood A.

Sci Rep. 2017 Sep 7;7(1):10797. doi: 10.1038/s41598-017-10983-x.

5.

SERPINB2 is regulated by dynamic interactions with pause-release proteins and enhancer RNAs.

Shii L, Song L, Maurer K, Zhang Z, Sullivan KE.

Mol Immunol. 2017 Aug;88:20-31. doi: 10.1016/j.molimm.2017.05.005. Epub 2017 Jun 1.

6.

microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.

Jin T, Suk Kim H, Ki Choi S, Hye Hwang E, Woo J, Suk Ryu H, Kim K, Moon A, Kyung Moon W.

Oncotarget. 2017 May 16;8(20):32769-32782. doi: 10.18632/oncotarget.15680.

7.
8.

Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation.

Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE.

Atherosclerosis. 2016 Jul;250:1-8. doi: 10.1016/j.atherosclerosis.2016.04.017. Epub 2016 Apr 21.

PMID:
27174532
9.

Variant of PAI-2 gene is associated with coronary artery disease and recurrent coronary event risk in Chinese Han population.

Li X, Luo JY, Zhang L, Yang YN, Xie X, Liu F, Chen BD, Ma YT.

Lipids Health Dis. 2015 Nov 16;14:148. doi: 10.1186/s12944-015-0150-y.

10.

The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2.

Zhang S, Zou L, Yang T, Yang Y, Zhai Z, Xiao F, Wang C.

Exp Cell Res. 2015 Mar 15;332(2):278-87. doi: 10.1016/j.yexcr.2015.02.006. Epub 2015 Feb 19.

PMID:
25704756
11.

SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.

Huang Z, Li H, Huang Q, Chen D, Han J, Wang L, Pan C, Chen W, House MG, Nephew KP, Guo Z.

Mol Carcinog. 2014 Oct;53(10):777-86. doi: 10.1002/mc.22033. Epub 2013 May 9.

PMID:
23661500
12.
13.

Secretion of SerpinB2 from endothelial cells activated with inflammatory stimuli.

Boncela J, Przygodzka P, Wyroba E, Papiewska-Pajak I, Cierniewski CS.

Exp Cell Res. 2013 May 1;319(8):1213-9. doi: 10.1016/j.yexcr.2013.02.018. Epub 2013 Mar 7.

PMID:
23474086
14.

Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.

Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC.

World J Surg. 2013 Mar;37(3):608-13. doi: 10.1007/s00268-012-1866-8.

PMID:
23188538
15.

Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator.

Stringer B, Udofa EA, Antalis TM.

J Biol Chem. 2012 Mar 23;287(13):10579-89. doi: 10.1074/jbc.M111.318758. Epub 2012 Feb 9.

16.

Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli.

Boncela J, Przygodzka P, Papiewska-Pajak I, Wyroba E, Cierniewski CS.

J Biol Chem. 2011 Dec 16;286(50):43164-71. doi: 10.1074/jbc.M111.245647. Epub 2011 Oct 5.

17.

Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.

Major L, Schroder WA, Gardner J, Fish RJ, Suhrbier A.

Exp Cell Res. 2011 Feb 1;317(3):338-47. doi: 10.1016/j.yexcr.2010.10.016. Epub 2010 Oct 23.

PMID:
20974129
18.

Role of plasminogen activator inhibitor-2 (PAI-2) in keratinocyte differentiation.

Jang S, Yang TH, An EJ, Yoon HK, Sohn KC, Cho AY, Ryu EK, Park YS, Yoon TY, Lee JH, Kim CD.

J Dermatol Sci. 2010 Jul;59(1):25-30. doi: 10.1016/j.jdermsci.2010.04.012. Epub 2010 May 21.

PMID:
20494554
19.

Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.

Akolekar R, Cruz Jde J, Penco JM, Zhou Y, Nicolaides KH.

Hypertens Pregnancy. 2011;30(2):194-202. doi: 10.3109/10641950903242675. Epub 2010 Mar 8.

PMID:
20205627
20.

Up-regulation of plasminogen activator inhibitor-2 is associated with high-risk HPV and grade of cervical lesion at baseline but does not predict outcomes of high-risk HPV infections or incident CIN.

Syrjänen S, Naud P, Sarian L, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Hammes LS, Costa S, Syrjänen K.

Am J Clin Pathol. 2009 Dec;132(6):883-92. doi: 10.1309/AJCPQQ07WUTZUTES.

PMID:
19926580

Supplemental Content

Support Center